Predictors and rate of adjuvant @entity1161 following radical prostatectomy: A report from the XXXX Registry.

@entity1 @entity137 @entity263 @entity1161 @entity5
INTRODUCTION: Long-term data from three randomized trials have demonstrated that adjuvant @entity1161 (ART) reduces the rate of biochemical failure in high-risk @entity1 following radical prostatectomy (RP). One of these trials has shown a survival advantage. We investigated the rate of ART in Victoria and the predictors for this treatment. METHODS: We analysed data from eligible @entity1 who were notified to the Victorian @entity263 Registry (PCR) by 37 Victorian hospitals between 1 August 2008 and 31 October 2011. We defined ART as @entity1161 ( @entity1161 ) delivered within 6 months of RP. Predictors of ART receipt were modelled using adjusted and unadjusted logistic regression. RESULTS: There were 4626 eligible cases from which 2018 underwent RP with recorded date of surgery. Of these eligible prostatectomy cases, a total of 89 received ART. A subgroup of 833 @entity1 had an adverse pathologic feature, of whom 78 received ART. In a multivariate model, pathologic @entity5 stage pT3a (odds ratio (OR) 2.64; 95% confidence interval (CI) 1.4-5.00; P   =   0.003), pT3b (OR 4.58; 95% CI 2.12-9.89; P   =   0.000), a positive surgical margin (OR 8.91; 95% CI 4.61-17.2; P   =   0.000) and pathologic Gleason grade >7 (OR 7.18; 95% CI 1.54-33.6; P   =   0.012) predicted receipt of ART. CONCLUSION: Adverse pathologic features and high pathologic Gleason score predict for receiving ART in Victorian @entity1 after RP, but overall, ART is not commonly prescribed. This finding is consistent with other published series and may reflect clinician scepticism regarding the benefit of ART over salvage @entity1161 and concern about @entity137 and the risk of over treatment.
